The Bond Group uses systems biology approaches to investigate the molecular pathogenesis of paediatric leukaemia, with a particular focus on epigenetic processes. The ultimate hope is to find more precise and effective cures for children and adolescents with blood cancers.
The Brennan Group's main research interests are in Obesity Related Carcinogenesis, Precision Medicine Solutions for Ovarian Cancer and Cancer Genomics.
The Eissner Group's major research focus is on endothelial and mesenchymal stem cells in transplant medicine and oncology, i.e. the monitoring and preventing endothelial-specific adverse immunological reactions in transplant settings and the development of new tumour-specific anti-angiogenic strategies in cancer. They aim to develop an individualised, risk-adapted approach to endothelial targeted protection in the course of allogeneic transplantation.
Gomez Matallanas Group
The Gomez Matallanas Group studies signalling networks in order to understand the fundamental properties that govern them and map new branches of these networks. In particular we focus on the MST2/Hippo pathway and the Ras family of oncogenes but given the multidisciplinary nature of SBI’s research we are also involved in several projects with other SBI researchers.
The Halasz Group (led by a Physician Scientist) have key interests in i) elucidating how the spatiotemporal dynamics of signal transduction networks contribute to the cancer cell phenotype, heterogeneity and resistance to treatment; and ii) applying this knowledge to develop novel therapeutic approaches and better personalized therapies to treat highly aggressive childhood cancers.
The Kholodenko Group focuses on Mathematical and Computational Modelling, Signal Transduction, Cancer and Precision Medicine.
The Kolch Group's current interest is in focusing on using computational modelling and omics approaches to analyse biological networks in order to elucidate the molecular mechanisms of disease such as cancer and inflammation (skin, rheumatoid arthritis), and in order to design new approaches to personalised diagnostics and treatment of these disease based on a systems level, molecular mechanistic understanding.
The Rauch Group focuses on elucidating the underlying mechanisms and the network adaptations of drug resistance in order to design personalized drug combinations that can avoid or overcome this resistance. In addition, they aim to derive diagnostic biomarkers that predict which drug combinations will be most effective for individual patients.
The Zhernovkov Group’s main research interest are in development of bioinformatics approaches to characterise the tumour immune microenvironment and cell-cell communication landscape in order to predict clinical outcomes and discover druggable molecular targets.